Escalier Biosciences Scores $19 Million in Funding Supporting Therapies for Psoriasis and Other Autoimmune Diseases

Escalier Biosciences and its dermatologic and autoimmune targets received a $19 million series B round funding from European Venture Capital firms Forbion, New Science Ventures and BioGeneration. 

“Escalier’s team has an impressive track record of developing novel compounds targeting diseases with significant unmet medical need,” stated Marco Boorsma, general partner at Forbion who will join Escalier’s board for financing. “We are excited to participate in this financing with New Science Ventures and BioGeneration Ventures and in supporting Escalier’s efforts to develop best-in-class drugs for the treatment of psoriasis and other autoimmune diseases.” 

The nuclear hormone receptor RORγt has emerged as the master regulator of Th17 cell differentiation and the production of pro-inflammatory cytokines. The funding will be used to create small molecule inhibitors of RORγt to lower the production of IL-17 in immune cells. Escalier is also developing both topical and oral RORγt drug candidates for psoriasis, and looks to begin clinicals with its topical compound in 2018.[1] 

“RORγt is a validated target for psoriasis and other autoimmune disorders and our drug candidates have the potential to provide the desired efficacy and safety in psoriasis patients that is currently unavailable with other topical or oral drugs,” said Raju Mohan, Ph.D., Chief Executive Officer of Escalier. “We are incredibly fortunate to have such a supportive syndicate of investors that share our passion in developing novel therapies for challenging targets such as RORγt.”

[1]https://www.prnewswire.com/news-releases/escalier-biosciences-raises-19-million-to-develop-its-topical-and-systemic-rort-therapies-for-psoriasis-and-other-autoimmune-diseases-300613033.html

Follow us on social media for the latest updates in B2B!

Latest

super bowl ad
Super Bowl LVII Ad Spots Sold Out. Why Did It Take So Long This Year?
February 6, 2023

Patrick Rishe, Host of “Suite Talk: The Business Behind Sports“, takes a look at the 2023 Super Bowl ad trends. An uncertain economy is one of the biggest factors as to why it took companies so long to buy out the ad spaces for this year’s Super Bowl. Not to mention we have seen nothing […]

Read More
Thoughts About Pro AV’s Path Forward in ’23
February 6, 2023

Can we take a second and acknowledge how impactful Gina Sansivero and Brandy Alvarado-Miranda are for our industry? … I had a chance to sit down with BOTH of them to break down some of the hottest trends from ISE this year, but also to dive deeper into the conversations and challenges that are […]

Read More
home intelligence
How Have Home Intelligence and Automated Shading Solutions Improved Home Energy Efficiency and Comfort?
February 6, 2023

On today’s episode of the Draper at Home podcast, host Michelle Dawn Mooney, speaks with Scotty Allen, the Chief Operating Officer of Josh.ai, Maryellen Oswald, Custom Integration & Partnerships Channel Manager, Somfy USA, and Tyson McDonald, Director of Business Development, Motorized Solar Solutions for Draper, Inc., to talk about how the effect of home intelligence […]

Read More